Pionyr Immunotherapeutics

8 articles with Pionyr Immunotherapeutics

• Pionyr Immunotherapeutics Adds Three Leading Oncology Researchers and Drug Developers to Scientific Advisory Board

  5/3/2022

  Pionyr Immunotherapeutics, Inc. announced today that Johanna Joyce, Ph.D., Olivier Elemento, Ph.D., and Michael Quigley, Ph.D., will join Miriam Merad, Ph.D., as members of Pionyr’s Scientific Advisory Board.

• Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314

  3/8/2022

  Pionyr Immunotherapeutics, Inc. announced that the first patient has been dosed in Phase 1b expansion studies investigating PY314 in patients with solid tumors.

• Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development

  3/29/2021

  The collaboration with Pionyr Therapeutics demonstrates Lonza’s flexibility to tailor its offering to accommodate the specific needs of our customers. Our team has created a cell line development program relying on a state-of-the-art platform technology that brings a faster and streamlined approach to selecting an ideal cell line.

• PIONYR Immunotherapeutics Initiates Phase 1 Clinical Study Of PY314

  11/18/2020

  Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's antitumor immunity by altering the composition and function

• 

  Gilead Continues Expansion into Oncology with Possible $1.75 Billion Deal with Pionyr

  6/23/2020

  Today, Gilead announced that it was acquiring a 49.9% equity interest in Pionyr Immunotherapeutics for $275 million and exclusive option to buy the rest of the company.

• PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages

  8/27/2019

  PIONYR Immunotherapeutics, Inc. announced the appointment of Alicia Levey, Ph.D., as Senior Vice President and Chief Business Officer.

• ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-oncology Contract Development and Manufacturing Project

  7/10/2018

  ProBioGen AG and Pionyr Immunotherapeutics, today announced a second service and license agreement to develop novel antibody therapeutics.

• 

  Bay Area's Pionyr Immunotherapeutics Scores $62M to Push Anti-Tumor Tech Towards Clinic

  12/13/2017

  Pionyr was founded in 2015 by a UCSF professor and a Genentech alum.